MWM
REGN icon

Mission Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Mission Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$846K Buy
1,357
+810
+148% +$551K 0.01% 529
2026
Q1 		$423K Sell
547
-42
-7% -$32.2K 0.01% 532
2025
Q4 		$454K Sell
589
-81
-12% -$55K 0.01% 509
2025
Q3 		$377K Sell
670
-81
-11% -$45.8K 0.01% 548
2025
Q2 		$394K Sell
751
-35
-4% -$19.5K 0.01% 533
2025
Q1 		$498K Buy
786
+254
+48% +$175K 0.01% 448
2024
Q4 		$379K Sell
532
-1,804
-77% -$1.51M 0.01% 498
2024
Q3 		$2.46M Buy
2,336
+409
+21% +$455K 0.06% 162
2024
Q2 		$2.03M Buy
1,927
+77
+4% +$74.6K 0.05% 169
2024
Q1 		$1.78M Buy
1,850
+1,379
+293% +$1.31M 0.05% 197
2023
Q4 		$414K Buy
471
+19
+4% +$15.6K 0.01% 416
2023
Q3 		$372K Hold
452
– – 0.01% 404
2023
Q2 		$325K Buy
452
+17
+4% +$13.1K 0.01% 439
2023
Q1 		$358K Buy
435
+15
+4% +$11.3K 0.02% 409
2022
Q4 		$303K Buy
+420
New +$310K 0.01% 420

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Mission Wealth Management's REGN Position: Q2 2026 in Review

Mission Wealth Management increased its Regeneron Pharmaceuticals (REGN) stake by 148% in Q2 2026, buying an estimated $551K and bringing the position to 1,357 shares worth $846K. The position accounts for 0.01% of the portfolio, ranked #529.

Mission Wealth Management first reported a position in REGN in Q4 2022 and has held it in 15 quarters since. The position peaked at $2.46M in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Mission Wealth Management held 1,357 shares of Regeneron Pharmaceuticals worth $846K as of Q2 2026.
  • Mission Wealth Management bought 810 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $551K.
  • Regeneron Pharmaceuticals made up 0.01% of Mission Wealth Management's portfolio in Q2 2026, its #529 holding.
  • Mission Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Mission Wealth Management's Regeneron Pharmaceuticals position peaked at $2.46M in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Mission Wealth Management's 13F filing for Q2 2026, filed 20 Jul 2026.